Permira, a investment firm, agreed to acquire Cambrex, a small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, for $2.4bn. Under the terms of the merger agreement, Cambrex shareholders will receive $60 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price. “We are excited to announce this transaction with Permira, a global private equity firm that has made significant investments in the pharma services space. This agreement is a strong endorsement of our strategy and represents significant value for our shareholders. Cambrex will continue to invest aggressively in our commitment to our global customer base, where we are constantly looking at ways to provide the broadest possible range of world class services,” Steve Klosk, Cambrex President and CEO.